GBI Research, Feb 2012, Pages: 290
, by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
- Develop key strategic initiatives by studying the key
GBI Research, Sep 2011, Pages: 142
includes monoclonal antibodies, insulins, interferons, growth hormones, colony stimulating factors, erythropoietins and blood factors. Furthermore, it includes market forecasts for each therapeutic class
Global Markets Direct, March 2011, Pages: 40
to buy
- Identify new drug targets and therapeutic classes in The Cancer Biotherapy Research Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit
GlobalData, Dec 2010, Pages: 42
to buy
- Identify new drug targets and therapeutic classes in The Cancer Biotherapy Research Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit
Global Markets Direct, Dec 2010, Pages: 42
to buy
- Identify new drug targets and therapeutic classes in The Cancer Biotherapy Research Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit
Biophoenix Limited, July 2009, Pages: 275
As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies to enter the biologics market, a segment which is uniquely
Frost & Sullivan, Oct 1997
Drugs Market
- Strategic Analysis and Forecasts of the European Antiviral Vaccines Market
- Strategic Analysis and Forecasts of the European Interferons Market
- Strategic Analysis and Forecasts
Cutting Edge Information, Feb 2009, Pages: 201
represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:
Drug history
Competitive and strategic positioning:
- Current status of drug
- Sales position
Markets and Markets, Sep 2009, Pages: 189
opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented
Global Industry Analysts, Inc., April 2009, Pages: 466
on Enquire before buying HEPATITIS C VIRUS AND THERAPEUTICS
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT
GlobalData, Nov 2010, Pages: 46
projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Synairgen plc’s strategic position with total access to detailed information on its product pipeline.
- Assess
Global Markets Direct, Nov 2010, Pages: 46
projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Synairgen plc’s strategic position with total access to detailed information on its product pipeline.
- Assess
Decision Resources, Inc., Sep 2011
The multibillion dollar biosimilars opportunity is an extremely attractive commercial prospect. A considerable volume of biosimilars research is under way in emerging markets. More global business
Decision Resources, Inc., June 2009, Pages: 31
opportunities, foreign companies will need to know how to navigate China’s complex healthcare system.”
- Neil Grubert, M.A., Director of Pricing and Reimbursement Research Executive Summary
Strategic
Datamonitor, June 2011, Pages: 199
another in terms of clinical and commercial attributes.
- Assessment of the strengths, weaknesses, opportunities, and threats for key marketed and pipeline therapies.
- Review of important clinical
